How to Read the Evidence Behind an Approved Aesthetic Procedure

The question behind every "clinically proven" claim

Reading the evidence behind an approved cosmetic procedure means asking one blunt question: what did the trial actually measure, and on whom? For botulinum toxin used on glabellar lines, the frown lines between the eyebrows, the answer is precise. Efficacy was measured with a four-point wrinkle scale, rated at maximum frown by both an independent investigator and the patient, under double-blind conditions, at a fixed follow-up visit, against a placebo injection. The approved claim is narrow and time-limited. Most marketing language is broader than the evidence that earned the approval. Learning to see that gap is the whole skill. This article is educational and is not medical advice.

What a cosmetic randomized trial actually measures

A pivotal aesthetic trial does not measure "younger" or "refreshed." It measures a defined change on a defined scale at a defined moment. For glabellar lines, the standard instrument is a four-point wrinkle severity scale, sometimes called the Facial Wrinkle Scale, often paired with a photonumeric guide: 0 is none, 1 is mild, 2 is moderate, 3 is severe. Trials enroll only people who start at 2 or 3, moderate to severe, because a scale cannot show improvement in a wrinkle that is already absent at rest. Assessment happens at maximum frown, when the person is actively contracting the corrugator and procerus muscles, not at a relaxed baseline. That detail matters. The endpoint captures dynamic lines produced by muscle contraction, which is exactly what the toxin acts on, and says nothing about static lines etched into the skin over years.

The review of onabotulinumtoxinA and abobotulinumtoxinA published in the journal literature (PMC2861845) lays out this design clearly: placebo-controlled, randomized, double-blind studies in which treatment success is defined as reaching a score of 0 or 1 at a set follow-up point, typically around day 30, with response peaking in the first two to four weeks. That is the shape of the evidence. A number, on a scale, at a time.

The value of a dual-rater endpoint

The more recent approvals raised the bar. The FDA prescribing information for daxibotulinumtoxinA (approved 2022) and its Drug Trials Snapshot define treatment success at Week 4 as a score of none or mild plus at least a two-point improvement from baseline, and that result has to hold for both the investigator's and the subject's rating. Requiring an expert and the patient to independently clear the same bar is a stricter test than either judgment alone. It guards against a clinician seeing improvement the patient does not feel, and against a hopeful patient reporting change an evaluator cannot see. When you read that a treatment "worked," check whether success meant one rating or two that had to agree.

Why validated scales and blinding carry the weight

Cosmetic outcomes are unusually vulnerable to bias because the result is subjective and the desire for it is strong. Two design features do most of the work to keep the finding honest.

First, the scale must be validated, meaning it has been tested so that different trained raters give the same score to the same face and the same rater is consistent over time. A photonumeric guide, where the rater compares the face to reference photographs, exists to make "moderate" mean the same thing across dozens of clinical sites. Without that, a trial measures the rater's mood, not the drug.

Second, blinding. In a double-blind trial neither the injector-evaluator nor the patient knows who received active toxin and who received saline. This is essential precisely because a wrinkle treatment produces expectations. An unblinded evaluator who knows a patient was treated tends to see success; a patient who knows tends to report it. The placebo arm exists to subtract that expectation effect. When a network meta-analysis of botulinum toxin formulations (PubMed 36097079) pooled randomized trials to compare products, its outputs were only as trustworthy as the blinded, scale-based endpoints feeding it: the percentage reaching a 0 or 1 score, and the percentage improving by one or two points, all assessed at maximum frown about a month out.

The approved indication is narrower than the marketing

Here is the disciplined reading. The FDA-approved indication for these products is the temporary improvement in the appearance of moderate to severe glabellar lines in adults. Every clause is a limit.

• Temporary. The effect fades over months. Trials measure a peak and a duration, not a permanent change.
• Improvement in the appearance. The claim is cosmetic and visual, not a change in skin biology or a health benefit.
• Moderate to severe. Studied in people starting at 2 or 3 on the scale. Mild lines were not the tested population.
• Glabellar lines. One region. An approval for frown lines is not evidence for forehead lines, crow's feet, or any other site unless that site was separately studied and cleared.
• Adults. The enrolled population, not everyone.

Marketing tends to blur each of these into a general promise of a smoother, younger face. The evidence supports a specific, reversible, region-limited change in a defined severity group. Use of the same product at other sites may be common in practice, but common is not the same as studied and approved, and the two should not be confused when you weigh the evidence.

A short checklist for reading any aesthetic trial

When you encounter a cosmetic procedure that claims clinical proof, ask:

• What scale, and is it validated? A named, photonumeric, reliability-tested scale beats a vague "significant improvement."
• Who was enrolled? The baseline severity and body region define what the result actually covers.
• Was it blinded and placebo-controlled? Subjective outcomes without blinding invite the expectation effect.
• Who rated the outcome, and did ratings have to agree? Independent investigator plus patient agreement is stronger than one judgment.
• At what time point, and for how long? A peak effect and its duration are different facts; a single flattering timepoint can hide a short-lived result.
• Does the approved indication match the claim being made to me? If the pitch is broader than the label, the extra breadth is not carrying trial-grade evidence.

The point is not skepticism for its own sake. Botulinum toxin for glabellar lines is one of the better-evidenced procedures in aesthetic medicine precisely because its trials were built around a validated scale, honest blinding, and a narrow, testable endpoint. That rigor is the reason to trust the specific claim, and the reason to be wary when a broader promise is dressed in the same lab coat.